TEVA Teva Pharmaceutical Industries Limited Loading... : Bullish and Bearish Analyst Opinions

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
22:07
Jul 29
Richard Francis CEO, Teva Pharmaceutical Bloomberg Markets
Long Teva, pipeline and volume growth
Teva delivered a strong Q2, raised guidance across all metrics, and sees upside in its key products. There is a large unmet patient need that will drive volume growth even as Medicare pricing rules impact pricing. The pipeline includes a Tourette's syndrome treatment with an expected approval around end of Q2 next year, and the company is well-positioned to maximize these opportunities.
TEVA 1ST
LOW

About TEVA Analyst Coverage

Buzzberg tracks TEVA (Teva Pharmaceutical Industries Limited) across 1 sources. 1 bullish vs 0 bearish calls from 1 analysts. Sentiment: predominantly bullish (100%). 1 total trade idea tracked. Latest voices: Richard Francis.